Milestones in the treatment of hepatocellular carcinoma: A systematic review.

被引：16

作者：

Gryziak, Maciej ^{[1
]}

Wozniak, Krzysztof ^{[1
]}

Kraj, Leszek ^{[1
,2
]}

Stec, Rafal ^{[1
]}

机构：

[1] Med Univ Warsaw, Dept Oncol, Warsaw, Poland

[2] Polish Acad Sci, Inst Genet & Anim Biotechnol, Dept Mol Biol, Jastrzebiec, Poland

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2021年 / 157卷

关键词：

hepatocellular carcinoma; liver cancer; systemic treatment; sorafenib; immunotherapy; DOUBLE-BLIND; PHASE-III; SORAFENIB TREATMENT; 2ND-LINE THERAPY; 1ST-LINE THERAPY; OPEN-LABEL; MULTICENTER; PLACEBO; CABOZANTINIB; REGORAFENIB;

D O I：

10.1016/j.critrevonc.2020.103179

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

According to data provided by WHO (World Health Organization), hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related deaths worldwide. Since the approval of sorafenib in 2008, several trials have assessed other particles for the treatment of HCC, but few have proven to be effective. ESMO (European Society for Medical Oncology) guidelines have been changed several times recently. This systematic review aims to describe both successful and failed trials of systemic treatments for HCC. Methods: We examined randomized, phase III trials of firstand second-line treatments in adults, identifying 23 fully-published trials and 2 reported as abstracts. The latest advances in immunotherapy were also briefly discussed. Conclusions: The landscape of HCC treatment has changed significantly in recent years. Several small molecule inhibitors currently form the core of HCC treatment; however, immunotherapy is now emerging as a promising treatment option.

引用

页数：9

共 42 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2] Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma [J].

Abou-Alfa, G. K. ;

Qin, S. ;

Ryoo, B-Y. ;

Lu, S-N. ;

Yen, C-J. ;

Feng, Y-H. ;

Lim, H. Y. ;

Izzo, F. ;

Colombo, M. ;

Sarker, D. ;

Bolondi, L. ;

Vaccaro, G. ;

Harris, W. P. ;

Chen, Z. ;

Hubner, R. A. ;

Meyer, T. ;

Sun, W. ;

Harding, J. J. ;

Hollywood, E. M. ;

Ma, J. ;

Wan, P. J. ;

Ly, M. ;

Bomalaski, J. ;

Johnston, A. ;

Lin, C-C. ;

Chao, Y. ;

Chen, L-T. .

ANNALS OF ONCOLOGY, 2018, 29 (06) :1402-1408

[3] Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Phase 3 CALGB 80802 Randomized Clinical Trial [J].

Abou-Alfa, Ghassan K. ;

Shi, Qian ;

Knox, Jennifer J. ;

Kaubisch, Andreas ;

Niedzwiecki, Donna ;

Posey, James ;

Tan, Benjamin R., Jr. ;

Kavan, Petr ;

Goel, Rakesh ;

Lammers, Philip E. ;

Bekaii-Saab, Tanios S. ;

Tam, Vincent C. ;

Rajdev, Lakshmi ;

Kelley, Robin K. ;

El Dika, Imane ;

Zemla, Tyler ;

Potaracke, Ryan, I ;

Balletti, Jennifer ;

El-Khoueiry, Anthony B. ;

Harding, James H. ;

Suga, Jennifer M. ;

Schwartz, Lawrence H. ;

Goldberg, Richard M. ;

Bertagnolli, Monica M. ;

Meyerhardt, Jeffrey ;

O'Reilly, Eileen M. ;

Venook, Alan P. .

JAMA ONCOLOGY, 2019, 5 (11) :1582-1588

[4] Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study [J].

Barbare, Jean-Claude ;

Bouche, Olivier ;

Bonnetain, Franck ;

Dahan, Laetitia ;

Lombard-Bohas, Catherine ;

Faroux, Roger ;

Raoul, Jean-Luc ;

Cattan, Stephane ;

Lemoine, Alain ;

Blanc, Jean-Frederic ;

Bronowicki, Jean-Pierre ;

Zarski, Jean-Pierre ;

Cazorla, Sophie ;

Gargot, Dany ;

Thevenot, Thierry ;

Diaz, Emmanuel ;

Bastie, Anne ;

Aparicio, Thomas ;

Bedenne, Laurent .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) :1788-1797

[5] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[6] Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study [J].

Bruix, Jordi ;

Tak, Won-Young ;

Gasbarrini, Antonio ;

Santoro, Armando ;

Colombo, Massimo ;

Lim, Ho-Yeong ;

Mazzaferro, Vincenzo ;

Wiest, Reiner ;

Reig, Maria ;

Wagner, Andrea ;

Bolondi, Luigi .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (16) :3412-3419

[7] Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial (vol 33, pg 172, 2015) [J].

Cainap, Calin .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (22) :2590-2590

[8] Chimeric antigen receptor-engineered T-cell therapy for liver cancer [J].

Chen, Yang ;

Chang-Yong, E. ;

Gong, Zhi-Wen ;

Liu, Shui ;

Wang, Zhen-Xiao ;

Yang, Yong-Sheng ;

Zhang, Xue-Wen .

HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2018, 17 (04) :301-309

[9] Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Lin, Deng-Yn ;

Park, Joong-Won ;

Kudo, Masatoshi ;

Qin, Shukui ;

Chung, Hyun-Cheol ;

Song, Xiangqun ;

Xu, Jianming ;

Poggi, Guido ;

Omata, Masao ;

Lowenthal, Susan Pitman ;

Lanzalone, Silvana ;

Yang, Liqiang ;

Lechuga, Maria Jose ;

Raymond, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4067-+

[10] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Chen, Zhendong ;

Tsao, Chao-Jung ;

Qin, Shukui ;

Kim, Jun Suk ;

Luo, Rongcheng ;

Feng, Jifeng ;

Ye, Shenglong ;

Yang, Tsai-Sheng ;

Xu, Jianming ;

Sun, Yan ;

Liang, Houjie ;

Liu, Jiwei ;

Wang, Jiejun ;

Tak, Won Young ;

Pan, Hongming ;

Burock, Karin ;

Zou, Jessie ;

Voliotis, Dimitris ;

Guan, Zhongzhen .

LANCET ONCOLOGY, 2009, 10 (01) :25-34

← 1 2 3 4 5 →